Amid rising agricultural complexity and the push for sustainability, genomics is at the forefront of innovation in breeding practices.

SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Illumina (NASDAQ: ILMN) a global leader in genomics, and LGC Biosearch Technologies™, a pioneer in agricultural genomics, today announced a strategic partnership to accelerate the adoption of genomics in agricultural applications. By combining Biosearch Technologies' targeted genotyping-by-sequencing library preparation methodology (Amp-Seq) with Illumina's proven and highly scalable sequencing technology, the partnership aims to deliver innovative solutions to researchers and breeders in the Asia Pacific (excluding China) and Latin America region.

SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL.

Today's judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger. The basis for the 432 million euro fine has now been removed and will no longer be payable.

Data Support Clinical Performance of Galleri to Detect More Aggressive Prostate Cancers

MENLO PARK, Calif., Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology. The data support the clinical performance of the Galleri test to preferentially screen for aggressive, clinically significant prostate cancer as compared to slow-growing (indolent) cases in the Circulating Cell-free Genome Atlas (CCGA) and PATHFINDER studies.

SAN DIEGO, Aug. 27, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient's solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. TSO Comprehensive is FDA approved as a CDx to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions that may benefit from treatment with Bayer's VITRAKVI® (larotrectinib). The test is also approved to identify adult patients with locally advanced or metastatic rearranged during transfection (RET) fusion-positive non-small-cell lung cancer (NSCLC) that may benefit from treatment with Lilly's RETEVMO® (selpercatinib).

-- Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio

-- Innovations to enable development of transformative applications using multiomics

-- Illumina to offer higher quality insights to customers, helping them improve the overall end-to-end workflow experience and lower cost

-- Delivering double digit to teens non-GAAP diluted earnings per share growth 2025-2027

-- Illumina and the Broad Institute of MIT and Harvard announce new research partnership to advance single-cell sequencing